Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback

Zai Lab's shares experienced a significant decline following disappointing Phase 3 trial results for its gastric cancer drug, bemarituzumab, which showed attenuated survival benefits, delaying regulatory filings by at least six months. This pipeline setback compounded investor concerns stemming from weaker-than-expected Q2 2025 sales of its core products, Zejula and Vyvgart, attributed to heightened market competition and pricing pressures. The dual blow underscores challenges to Zai Lab's 'license-in' strategy, prompting a strategic pivot towards self-developed R&D, and has led to a lower market valuation compared to peers.

Analysis

Zai Lab is facing a dual crisis of confidence stemming from both a significant clinical pipeline setback and deteriorating commercial performance. The primary catalyst for the negative sentiment is the attenuated survival benefit observed in the final Phase Three analysis for its gastric cancer drug, bemarituzumab, which has delayed potential regulatory filings by at least six months to late 2025 or H1 2026. This news triggered an 11.99% drop in its Hong Kong-listed shares. Compounding this issue are the company's Q2 2025 earnings, which missed market expectations. While revenue grew 9% to $110 million, sales of its most lucrative drug, Zejula, fell 8.8% year-over-year to $41 million due to intense price competition. Similarly, sales of its other key product, Vyvgart, grew 14.5%, falling short of the 20-25% expected growth, with the looming threat of a new competitor from RemeGen potentially eroding its pricing advantage. These commercial and clinical challenges cast doubt on Zai Lab's ability to meet its full-year revenue guidance of $560-$590 million, which now requires formidable second-half growth of 63-77%. The firm's valuation, at a price-to-sales ratio of approximately 8 times, is substantially lower than peers like Everest Medicines (22 times), reflecting significant market skepticism about its near-term outlook and the viability of its 'license-in' strategy, prompting a pivot to self-developed R&D.

Key Decisions for Investors

• Investors should recognize the heightened risk profile driven by the bemarituzumab trial setback and weakening fundamentals of core products, which makes achieving the company's full-year guidance and Q4 profitability target highly challenging.
• Monitor competitive and pricing pressures on Zejula and Vyvgart, as any further erosion in sales could signal deeper issues with the company's commercial execution and invalidate its near-term financial projections.
• While the valuation discount to peers is notable, the investment thesis now hinges on the long-term success of the strategic pivot to in-house R&D, making progress on pipeline candidates like ZL-1310 a critical catalyst to watch.